1. Identification of rare-disease genes using blood transcriptome sequencing and large control cohorts
- Author
-
Diane B. Zastrow, Cameron J. Prybol, Jason D. Merker, Benjamin J. Strober, Euan A. Ashley, Zachary Zappala, Jennefer N. Kohler, Sowmithri Utiramerur, Chloe M. Reuter, Xin Li, Kevin S. Smith, Alexis Battle, Joe R. Davis, Craig Smail, Devon Bonner, Taila Hartley, Shruti Marwaha, Matthew T. Wheeler, Boxiang Liu, Stephen B. Montgomery, Nicole M. Ferraro, Lars Lind, Dianna G. Fisk, Brunilda Balliu, Nicole A. Teran, Erik Ingelsson, Laure Fresard, Gill Bejerano, Megan E. Grove, Ruchi Joshi, Kym M. Boycott, Jonathan A. Bernstein, Kristin D. Kernohan, and Jean M. Davidson
- Subjects
Male ,0301 basic medicine ,Oxidoreductases Acting on CH-CH Group Donors ,Candidate gene ,medicine.medical_specialty ,Potassium Channels ,Acid Ceramidase ,RNA Splicing ,Disease ,Biology ,Bioinformatics ,Article ,General Biochemistry, Genetics and Molecular Biology ,DNA sequencing ,Cohort Studies ,03 medical and health sciences ,Rare Diseases ,0302 clinical medicine ,Exome Sequencing ,medicine ,Humans ,Child ,Exome sequencing ,Models, Genetic ,Sequence Analysis, RNA ,Case-control study ,Genetic Variation ,General Medicine ,Disease gene identification ,3. Good health ,030104 developmental biology ,Case-Control Studies ,Child, Preschool ,030220 oncology & carcinogenesis ,Mutation ,RNA ,Medical genetics ,Female ,Rare disease - Abstract
It is estimated that 350 million individuals worldwide suffer from rare diseases, which are predominantly caused by mutation in a single gene1. The current molecular diagnostic rate is estimated at 50%, with whole-exome sequencing (WES) among the most successful approaches2–5. For patients in whom WES is uninformative, RNA sequencing (RNA-seq) has shown diagnostic utility in specific tissues and diseases6–8. This includes muscle biopsies from patients with undiagnosed rare muscle disorders6,9, and cultured fibroblasts from patients with mitochondrial disorders7. However, for many individuals, biopsies are not performed for clinical care, and tissues are difficult to access. We sought to assess the utility of RNA-seq from blood as a diagnostic tool for rare diseases of different pathophysiologies. We generated whole-blood RNA-seq from 94 individuals with undiagnosed rare diseases spanning 16 diverse disease categories. We developed a robust approach to compare data from these individuals with large sets of RNA-seq data for controls (n = 1,594 unrelated controls and n = 49 family members) and demonstrated the impacts of expression, splicing, gene and variant filtering strategies on disease gene identification. Across our cohort, we observed that RNA-seq yields a 7.5% diagnostic rate, and an additional 16.7% with improved candidate gene resolution. A diagnostic tool based on blood RNA-seq is shown to identify causal genes and variants linked to clinical phenotypes in individuals with rare diseases for which whole-exome genetic sequencing was uninformative.
- Published
- 2019
- Full Text
- View/download PDF